Direct switch from an efavirenz-based regimen to intramuscular long-acting cabotegravir plus rilpivirine: A case report

Abstract

Switching from oral antiretroviral treatment to intramuscular (IM) cabotegravir (CAB) + rilpivirine (RPV) has an optional oral lead-in to ensure tolerability. The British HIV Association guidelines advise against directly switching from oral antiretroviral (ART) combinations containing strong/moderate cytochrome inducers like efavirenz (EFV) to IM CAB + RPV. EFV has a prolonged elimination half-life, leading to a residual induction of UGT1A1 and CYP3A4 after discontinuation. These enzymes are responsible for CAB and RPV metabolism and their induction might lead to sub-optimal concentrations of CAB and RPV, risking drug resistance. When switching from EFV to oral CAB + RPV, the ATLAS and ATLAS 2M studies showed reduced RPV concentrations but with maintained viral suppression during the oral lead-in and subsequent long-acting injectable (LAI) phases. Also, a recent pharmacokinetic modelling study indicated reduced RPV concentrations, without viral implication, when switching from EFV to IM CAB + RPV. However, there are limited real-world data on direct switching from EFV-based therapy to long-acting IM CAB + RPV. We describe a case where oral intake was impossible in a critical care scenario, switching from emitricitabine/tenofovir-DF (FTC/TDF) 200/245 mg + 600 mg EFV to IM CAB + RPV for treatment optimisation.

Keywords

Treatment (antiretroviral therapy)

Get full access to this article

View all access options for this article.

References

Orkin

Bernal Morell

Tan

DHS

, et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lan HIV 2021; 8: e668–e678.

U.S Food and Drug Administration . Cabenuva product label. U.S Food and Drug Administration, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf

Waters

Winston

Reeves

, et al. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022. HIV Med 2022; 23: 3–115.

University of Liverpool Drug Interaction Database, 2023. https://www.hiv-druginteractions.org/checker

Hodge

Back

Gibbons

, et al. Pharmacokinetics and drug–drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet 2021; 60: 835–853.

Ramgopal

Castagna

Cazanave

, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lan HIV 2023; 10: e566–e577.

Jaeger

Overton

Richmond

, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lan HIV 2021; 8: e679–e689.

Overton

Richmond

Rizzardini

, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet 2021; 396: 1994–2005.

Bettonte

Berton

Stader

, et al. Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen. Br J Clin Pharmacol. 2023; 1–11.

10.

Formulations

LD.

Crushing and liquid ARV formulations. HIVCLINIC.ca. Accessed June 2023, https://www.hivclinic.ca/main/drugs_extra_files/Crushing%20and%20Liquid%20ARV%20Formulations.pdf

11.

Ryom

Cotter

De Miguel

, et al. 2019 update of the European AIDS clinical society guidelines for treatment of people living with HIV version 10.0. HIV Med 2020; 21: 617–624.

12.

Margolis

Brinson

Smith

GHR

, et al. LAI116482 Study Team

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis 2015; 15: 1145–1155.

13.

Han

Baker

Lovern

, et al. Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects. Br J Clin Pharmacol 2022; 88: 4607–4622.

14.

D’Amico

Cenoz Gomis

Moodley

, et al. Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy. HIV Med 2023; 24: 202–211.